scispace - formally typeset
Journal ArticleDOI

Improved Graft Survival after Renal Transplantation in the United States, 1988 to 1996

TLDR
There has been a substantial increase in short-term and long-term survival of kidney grafts from both living and cadaveric donors since 1988.
Abstract
Background The introduction of cyclosporine has resulted in improvement in the short-term outcome of renal transplantation, but its effect on the long-term survival of kidney transplants is not known. Methods We analyzed the influence of demographic characteristics (age, sex, and race), transplant-related variables (living or cadaveric donor, panel-reactive antibody titer, extent of HLA matching, and cold-ischemia time), and post-transplantation variables (presence or absence of acute rejection, delayed graft function, and therapy with mycophenolate mofetil and tacrolimus) on graft survival for all 93,934 renal transplantations performed in the United States between 1988 and 1996. A regression analysis adjusted for these variables was used to estimate the risk of graft failure within the first year and more than one year after transplantation. Results From 1988 to 1996, the one-year survival rate for grafts from living donors increased from 88.8 to 93.9 percent, and the rate for cadaveric grafts increased...

read more

Citations
More filters
Journal ArticleDOI

Ciclosporina A e tacrolimus: uma revisão

TL;DR: In this paper, a monitorizacao terapeutica de imunossupressores ciclosporina A (CsA) and tacrolimus (FK506) is presented, with the aim of evitando para o transplantado a perda do enxerto, no caso de baixas doses, ou a toxicidade, em altas doses.
Journal ArticleDOI

Mycophenolic acid formulations in adult renal transplantation - update on efficacy and tolerability.

TL;DR: The clinical trials that have evaluated the efficacy and safety of MPA in adult kidney transplantation for the prevention of acute rejection and their use in new combination regimens aiming at minimizing calcineurin inhibitor toxicity and chronic allograft nephropathy are discussed.
Journal ArticleDOI

The economics of basiliximab (Simulect) in preventing acute rejection in renal transplantation.

TL;DR: In this article, an economic evaluation was conducted alongside a multicentre international trial of basiliximab and no statistically significant differences were found in the mean cost of treatment per patient, with a mean difference of $1,660 (95% confidence interval (CI): −$4,150, $7,360; P=0.58).
Journal ArticleDOI

Computer-assisted cyclosporine dosing performs better than traditional dosing in renal transplant recipients: results of a pilot study.

TL;DR: The computer-assisted TDM-targeted CsA blood concentrations significantly better than experienced transplant physicians are compared, and a possible favorable effect on short- and long-term outcome needs to be verified in further, properly powered, clinical trials.
Journal ArticleDOI

Economic impact and long-term graft outcomes of mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant recipients.

TL;DR: D dosage reduction or discontinuation of mycophenolate mofetil in the first 6 months after diagnosis of GI complications is associated with significantly increased risk of graft failure and increased healthcare costs in adult renal transplant recipients.
References
More filters
Book ChapterDOI

Nonparametric Estimation from Incomplete Observations

TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Journal ArticleDOI

Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.

TL;DR: This study demonstrated that MMF administered at a dosage of 2 g or 3 g daily, in combination with maintenance CsA and corticosteroids as triple therapy following ATGAM® induction therapy, is more effective than an otherwise identical regimen that includes azathioprine instead of MMF in preventing acute allograft rejection in first cadaveric renal transplant patients.
Journal ArticleDOI

A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group

TL;DR: Tacrolimus is more effective than cyclosporine in preventing acute rejection in cadaveric renal allograft recipients, and significantly reduces the use of antilymphocyte antibody preparations.
Journal ArticleDOI

Risk factors for chronic rejection in renal allograft recipients.

TL;DR: In this article, the authors found that acute rejection, CsA dosage < 5 mg/kg/day at 1 year, and infection are the major risk factors for the development of chronic rejection.
Related Papers (5)